Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy
Crossref DOI link: https://doi.org/10.1007/s11912-022-01215-1
Published Online: 2022-02-22
Published Print: 2022-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Chitturi, Kalyan R.
Burns, Ethan A.
Muhsen, Ibrahim N.
Anand, Kartik
Trachtenberg, Barry H.
Text and Data Mining valid from 2022-02-22
Version of Record valid from 2022-02-22
Article History
Accepted: 1 December 2021
First Online: 22 February 2022
Declarations
:
: The authors declare no competing interests.